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Cidofovir is an antiviral with a broad spectrum of activity against DNA viruses, and has been reported to be one of the most effective agents to inhibit HHV-8 replication in vitro. 2 In addition to its antiviral activity, a potent antitumor activity has been recently attributed to cidofovir. [3] [4] [5] Topical application of cidofovir resulted effective to treat both neoplastic genital lesions and recurrent laryngeal papillomatous lesions caused by human papillomavirus (HPV). 3, 4 In animal models, cidofovir has been found to be effective on virus-associated tumors, such as in nude mice with EBV-associated nasopharyngeal carcinoma, in which intratumoral injection of cidofovir induced in vivo regression of the tumors. 5 The antitumor activity of cidofovir is not specifically related to the antiviral action of the compound. Consistent with this, cidofovir has also been shown to inhibit the growth of tumors, such as hemangiosarcomas, which are not associated with oncogenic viruses. 6 In the current study, we tested whether cidofovir exerts an antitumor effect against two PEL cell lines in vitro, namely the HHV-8-positive BCBL-1 and the HHV-8-positive and EBVpositive HBL-6 cell lines. The EBV-negative and HHV-8-negative RAMOS cell line was tested as control. Then, we investigated the effect of intracavity injections of cidofovir for the treatment of three elderly, HIV negative, patients with PEL.
The BCBL-1, HBL-6 and the RAMOS cell lines were cultured in RPMI 1640 medium, supplemented with 15% of heat inactivated fetal calf serum (FBS), glutamine 1 mM and antibiotics, at 371C in a 5% CO 2 humidified incubator. Cells were treated with cidofovir at 0.01, 0.1, 0.5, and 1 mM, for 3 and 6 days. At the end of the incubation period, cell count and viability were evaluated in triplicate, with Trypan blue dye exclusion assay. Apoptosis was studied by a combination of methods, including, morphology, propidium iodide staining (50 mg/ml) and analysis by flow cytometry (Becton and Dickinson Italia, Milano, Italy), the DNA fragmentation assay, and the in situ cell death detection kit (Boheringer Mannheim, Mannheim, Germany), which relies on the use of terminal deoxynucleotidyl transferase (TdT) that catalyses the polymerization of fluorescein-labeled nucleotides to free 3 0 -hydroxyl residues of DNA fragments generated by endonucleases during apoptosis (TUNEL). 6, 7 Cidofovir caused a dose-dependent inhibition of BCBL-1 and HBL-6 cell proliferation and viability (Figure 1a-d) , while in RAMOS cells, cidofovir inhibited proliferation but had no effect on viability (Figure 1e and f). Cidofovir induced a dose-dependent apoptosis in both the BCBL-1 and HBL-6 cell lines, after 3 and 6 days, as detected by flow cytometry analysis (Figure 2a In three patients, (pt. 1, pt. 2 and pt. 3) a diagnosis of HHV-8-positive PEL, in Ann Arbor stage IV, was made, on the basis of morphologic, immunophenotypic and molecular analysis, as described. 1 EBV coinfection was documented in pt. 1, while serology for HIV, hepatitis B and C viruses was negative in all three patients. In detail, pt. 1, a 96-year-old Italian man, was hospitalized for bilateral pleural effusion. No clinical evidence of KS was found. The patient was subjected to pleural drainage every 2 weeks for 4 months, without receiving any chemotherapy. Then, he was treated with two doses of intrapleura cidofovir, at 2.5 mg/kg, every 1 week. No recurrence of pleural effusion was observed after the second injection. PEL relapsed at the same site, as documented on standard radiographic examination, 10 months later. The patient refused cidofovir therapy and was subjected to pleural drainage. The patient died for heart failure. Pt. 2, a 70-year-old Italian man, was hospitalized for recurrent peritoneal effusions. The patient had a history of KS, for which he had received chemotherapy and radiotherapy 10 years before, with complete tumor regression. The patient was subjected to peritoneal drainages every 10 days for 2 months. Then, the patient received three doses of intraperitoneal cidofovir, at 5 mg/kg, every 1 week. No recurrence of peritoneal effusion was observed after the last cidofovir injection. PEL relapse was documented in the pleura 5 months later. The patient died for a cerebrovascular accident, with no peritoneal relapse. Pt. 3, a 77-year-old Italian man, was hospitalized for a 5-month history of bilateral pleural effusion requiring repeated pleural drainages. Chemotherapy was avoided because the patient had been suffering from heart failure. He was treated with three doses of intrapleura cidofovir, at 5 mg/Kg, every 1 week. Bilateral uveitis developed 1 week after the last cidofovir injection, which resolved only partially, with low-dose steroid therapy. Mild renal insufficiency (creatinine, 2.5 mg/dl) developed 2 weeks after the last cidofovir injection and persisted. After 8 months, the patient had a myocardial infarction and renal function progressively deteriorated (creatinine, 9 mg/dl), although dialysis was never required. After 15 months after treatment the patient is still alive, without PEL recurrence. Remission in all the three patients was confirmed by negative findings both on repeated standard chest X-ray and total body CT scans. Prehydration and probenecid were coadministered with intracavity cidofovir in all the three patients to reduce the risk of nephrotoxicity, as recommended in the course of intravenous administration of cidofovir. Cidofovir was administered on a compassionate use, after each patient's informed consent had been obtained. No other antivirals were administered to the three patients. It should be noted that by intravenous administration of cidofovir at 5 mg/kg an average peak serum level of cidofovir of 30-70 mM can be achieved, at which, however, no proapoptotic effect is expected to occur in vivo, on the basis of the in vitro findings described above. Thus, we hypothesized that injection of cidofovir into the limited space of a body cavity would have allowed to achieve higher concentrations of the drug in vivo, possibly comparable to the concentrations required to induce the proapoptotic effect documented in vitro. This was indeed the case, as after two intrapleural injections of cidofovir in pt. 1 and three intraperitoneal and intrapleural injections of cidofovir in pts. 2 and 3, respectively, a significant clinical effect was obtained. Neither local nor significant systemic toxic effects were observed, except for renal and ocular alterations in pt. 3. Such toxic effects were observed neither in pt. 2, treated with the same doses but with a different administration route (intraperitoneal vs intrapleural), nor in pt. 1, who was, however, treated with only two injections of half of the recommended intravenous dose. Unfortunately, neither blood nor intracavity levels of cidofovir were available to be correlated with either the response or the toxic effects found in these patients. Very recent data from cidofovir plasma assays after local injection in respiratory papillomatosis suggest that, because of the great individual variation in diffusion of cidofovir from the injected sites, this compound should be used at less than the recommended intravenous dose, to prevent any risk of systemic toxicity. 4 It is clear that further clinical studies combined with cidofovir plasma assays are warranted to find out the optimal dose of cidofovir for intracavity injections, especially in elderly patients with PEL, who may have concurrent diseases and/or predisposing factors to renal failure, like pt. 3, suffering from cardiovascular disease and hypertensive arteriopathy.
Our data show that the direct antitumor activity of high concentration cidofovir against PEL in vitro is mediated by tumor cell apoptosis. Further studies are needed to elucidate the mechanism(s) of cidofovir-induced apoptosis of PEL cells. Although spontaneous regression of PEL has been exceptionally reported, it is highly unlikely that this occurred in our patients, who had been presenting recurrent effusions for several months, before initiation of therapy, and showed a rapid and complete remission of PEL only immediately after the few injections of cidofovir. PEL is usually highly aggressive in the HIV positive and the few transplant patients reported so far. The natural history of PEL in the HIV-negative elderly patients is more heterogeneous. A recent review of the reported cases in the literature has shown that in 10 of 14 patients for whom a followup was available, death had occurred within 8 months, while in the remaining four patients the clinical course had been more favorable, with remission duration of 13, 16, 18 and 72 months, respectively) (reference in supplementary information). Given the very low number of the reported cases, and the old age of these patients with PEL, who had often died of causes unrelated to the tumor, the clinical outcome and prognosis of this lymphoma subtype is not well defined. PEL is often resistant to common chemotherapeutic agents, so that the intracavity injections of cidofovir should be considered as a possible, and relatively safe, therapeutic option. The duration of the remission obtained in these three patients has been of 5-15 months, so that a combination of intracavity cidofovir with other nonchemotherapeutic agents, such as interferon and azidothimidine, recently found to induce apoptosis on herpesvirus-associated lymphomas, 8 could be usefully considered. Although most PEL cells are latently infected with HHV-8, a small subpopulation of cells does support lytic viral growth, so that the development and/or the maintenance of PEL may require de novo infection of lymphoma cells by a virus released from lytically infected cells. 2 In such a view, intravenous administration of cidofovir could also be considered in addition to intracavity administration, to achieve inhibition of HHV-8 replication, in infected patients. The class III receptor tyrosine kinases (RTKs), which include c-FMS, c-KIT, FLT3, platelet-derived growth factor receptor a (PDGFRA) and b (PDGFRB), have been reported to be associated with the pathogenesis of an increasing number of malignancies. 1,2 PDGFRA and c-KIT are two related RTKs showing similar structure, and mutations of these genes are detected in gastrointestinal stromal tumor (GIST). 3, 4 Recently, a c-KIT D816V-activating mutation in the second tyrosine kinase (TK2) domain has been reported in patients having acute myeloid leukemia (AML) with t(8;21)(q22;q22) or inv(16)(p13q22). 5 Hence, we speculated that PDGFRA is also implicated in the pathogenesis of AML, and the mechanisms of cytogenetic progression and oncoprotein-driven function may be similar in AML expressing oncogenic forms of PDGFRA and c-KIT.
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A total of 69 leukemia cell lines and 114 childhood AML samples, including those from 14 patients with t(8;21)(q22;q22) and two patients with inv(16)(p13q22) were analyzed for the expression and mutation of PDGFRA. Informed consent was obtained from the patients and/or their parents. PDGFRA gene was expressed in 28 (40.6%) of the 69 leukemic cell lines and 63 (55.3%) of the 114 AML patient samples, and direct sequencing of the samples expressing PDGFRA revealed a PDGFRA N870S mutation in a 13-yearold boy having AML-M1 with t(8;21) and a F808L mutation in a 13-year-old girl having AML-M1 with inv(16) (Figure 1a) . These missense mutations in the TK2 domain of PDGFRA are homologous to those responsible for KIT and FLT3 ligandindependent kinase activation in GIST, 3 mast cell disorders 6 and AML 7, 8 (Figure 1b) . Exon 17 mutations of Asp 816 in the TK2 domain of c-KIT are associated with mast-cell/myeloid leukemias and seminomas/dysgerminomas. 1 The transforming mechanism for these mutations is considered to involve dimer formation, resulting in constitutive ligand-independent kinase activation. 1 The PDGFRA expression was found in AML with core binding factor (CBF) translocations; 12 (85.7%) of the 14 patients with t(8;21) and two (100%) of the two patients with inv(16). The expression rate of PDGFRA in AML with CBF translocations (14 of the 16 patients, 87.5%) was significantly higher than in AML with other karyotypes (49 of the 98 patients, 50%; P ¼ 0.0059). Tumors expressing PDGFRA or KIT oncoproteins were indistinguishable with respect to activation of downstream signaling associated with tumor progression. Oncoprotein-driven signal transduction in AML is similar in GIST expressing oncogenic forms of PDGFRA and KIT.
